- Home
- QXO vs RVMD Comparison
QXO vs RVMD Comparison
Compare QXO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | RVMD |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 15.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QXO | RVMD |
|---|---|---|
| Price | $19.39 | $79.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | $33.08 | ★ $77.47 |
| AVG Volume (30 Days) | ★ 6.3M | 2.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,662,873,000.00 | N/A |
| Revenue This Year | $12,116.69 | N/A |
| Revenue Next Year | $61.67 | $714.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8107.98 | N/A |
| 52 Week Low | $11.85 | $29.17 |
| 52 Week High | $24.69 | $81.97 |
Technical Indicators
Market Signals| Indicator | QXO | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 63.61 |
| Support Level | $21.20 | $78.97 |
| Resistance Level | $22.19 | $81.97 |
| Average True Range (ATR) | 0.63 | 2.21 |
| MACD | -0.27 | -0.53 |
| Stochastic Oscillator | 0.17 | 77.26 |
Price Performance
Historical ComparisonAbout QXO QXO Inc.
QXO Inc is the publicly traded distributor of roofing, waterproofing and complementary building products in the United States. The company aims to become the tech-enabled leader in the approximately $800 billion building products distribution industry and generate outsized value for shareholders. It is targeting nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.